AcuFocus adds $21 million to its coffers as it waits on word from the FDA on its Kamra inlay, which is designed to treat near vision loss.
AcuFocus said today that it raised another $21 million in an oversubscribed round as it awaits a decision from the FDA on its Kamra device, a corneal inlay designed to treat near vision loss, or presbyopia.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1ttrnTK
Cap comentari:
Publica un comentari a l'entrada